Journal of Drug Delivery and Biotherapeutics (JDDB)

(E-ISSN: 3049-1177)

Journal homepage: https://sennosbiotech.com/JDDB/1

Review Article

Microneedle-Based Drug Delivery: Revolutionizing Transdermal Therapeutics for Painless and Precise Administration

Dr. Jeevan Rajguru

[1]Department of Pharmaceutics, AAEMF's Delight Institute of Pharmacy,Koregaon Bhima, Tal-Shirur, Pune, Maharashtra India

ARTICLEINFO

ABSTRACT

Microneedle-based drug delivery systems have emerged as a transformative platform in transdermal therapeutics, offering a minimally invasive, painless, and highly targeted alternative to conventional drug administration routes. These systems consist of micron-scale needles that can penetrate the stratum corneum without reaching pain receptors, enabling efficient delivery of a wide range of therapeutic agents—including small molecules, proteins, peptides, and vaccines—directly into the dermis. Various types of microneedles, such as solid, coated, dissolvable, and hollow designs, have been engineered using biocompatible and biodegradable materials to suit specific clinical applications. Microneedles not only improve patient compliance but also bypass hepatic first-pass metabolism and allow self-administration. Recent advancements have shown significant promise in applications such as insulin delivery, vaccine immunization, and cancer therapy. Despite their potential, challenges remain in terms of large-scale manufacturing, regulatory approval, and long-term skin safety. This review highlights the current progress, design strategies, clinical applications, and future prospects of microneedle-based drug delivery systems in revolutionizing patient-centric transdermal therapy.

Keywords: Microneedles, Transdermal Drug Delivery, Minimally Invasive Systems, Controlled Release, Patient Compliance

Corresponding Author:

Dr. Jeevan Rajguru

E-mail addresses: jeevanrajguru97@gmail.com

Received date: 07-Mar-2025 Revised date: 29-Mar-2025, Accepted date: 10-Apr-2025

1. Introduction

Transdermal drug delivery has long been recognized as an attractive alternative to oral and injectable routes due to its potential to bypass hepatic first-pass metabolism, reduce systemic side effects, and improve patient compliance. However, the effectiveness of traditional transdermal patches is limited by the skin's natural barrier, particularly the stratum corneum, which restricts the passive diffusion of most therapeutic agents—especially large molecules and biologics [1-3].

To overcome these challenges, microneedle-based drug delivery systems (MNDDS) have emerged as a groundbreaking innovation. Microneedles are micron-scale projections, typically ranging from 50 to 900 µm in length, capable of painlessly breaching the outermost layer of the skin to deliver drugs directly into the epidermis or dermis. This minimally invasive approach enables efficient and precise delivery of a wide variety of compounds, including small molecules, peptides, proteins, vaccines, and even genetic materials [4-5].

Microneedles combine the benefits of both transdermal and injectable delivery—offering needle-free administration while ensuring enhanced bioavailability and rapid onset of action. They also support self-administration, making them especially advantageous in chronic therapies, pandemic vaccinations, and low-resource settings. Over the past two decades, various types of microneedles—solid, coated, dissolvable, hollow, and hydrogel-forming—have been developed using biocompatible and biodegradable materials, each suited for specific delivery strategies and drug profiles [6].

With increasing evidence from preclinical and clinical studies, microneedle systems have demonstrated potential across diverse therapeutic areas, including diabetes management, cancer therapy, immunization programs, and cosmetic applications. Despite their advantages, there remain challenges related to scalability, device standardization, regulatory approval, and long-term skin safety [7-9].

This review provides a comprehensive overview of microneedle-based drug delivery systems, focusing on their design, fabrication techniques, drug release mechanisms, current clinical applications, and the challenges and opportunities that lie ahead in translating this promising technology to widespread clinical use [10].

2. Types of Microneedles

Microneedle technology has evolved significantly to accommodate diverse therapeutic needs. Based on their structure, mechanism of drug release, and material composition, microneedles are generally classified into five main types: solid, coated, dissolving, hollow, and hydrogel-forming microneedles. Each type offers unique advantages and is suited for different drug delivery strategies [11-12].

2.1 Solid Microneedles

Solid microneedles are typically made from metal, silicon, or polymers and are used to create microchannels in the skin through which drug molecules can later diffuse. This "poke-and-patch" approach involves pre-treating the skin with microneedles followed by application of a drug-loaded patch or topical formulation. Although simple in design, solid microneedles require a two-step process and may not ensure uniform drug penetration [13-15].

2.2 Coated Microneedles

Coated microneedles are fabricated by applying a thin layer of drug formulation onto the surface of solid microneedles. Upon insertion into the skin, the drug coating dissolves rapidly, allowing for immediate drug release. This type is suitable for delivering potent drugs and vaccines in small doses. However, limitations include low drug-loading capacity and challenges in achieving uniform coating across needles [16].

2.3 Dissolving Microneedles

Dissolving microneedles are made from biodegradable and water-soluble polymers such as hyaluronic acid, carboxymethyl cellulose, or polyvinylpyrrolidone. These microneedles encapsulate the drug within their structure and dissolve completely upon skin insertion, eliminating biohazardous sharp waste. They are ideal for sustained release and single-step administration, with excellent safety profiles [17-18].

2.4 Hollow Microneedles

Hollow microneedles resemble traditional hypodermic needles on a microscale and deliver drugs in liquid form through a central bore. They allow controlled infusion of larger drug volumes, making them suitable for biologics and vaccines. However, they are more complex to manufacture and may be prone to clogging or mechanical failure during insertion.

2.5 Hydrogel-Forming Microneedles

Hydrogel-forming microneedles are composed of crosslinked polymer networks that swell upon absorbing interstitial fluid from the skin. Unlike dissolving microneedles, they do not dissolve but act as conduits for sustained drug diffusion from an attached reservoir. These systems are particularly advantageous for extended release and reduced dosing frequency in chronic therapy.

Each microneedle type presents unique design opportunities and formulation considerations. Selection depends on factors such as drug stability, dose requirement, duration of therapy, and patient compliance. As research progresses, hybrid and multifunctional microneedle systems are also being developed to combine the strengths of various types.

3. Fabrication Techniques of Microneedles

The fabrication of microneedles requires precision, reproducibility, and compatibility with both structural integrity and drug incorporation. The selection of the fabrication method depends on the microneedle type, material properties, drug sensitivity, and intended application. A range of techniques has been employed for microneedle production, including micromolding, photolithography, laser cutting, drawing lithography, and 3D printing [19].

Micromolding is the most widely used technique, particularly for dissolving and hydrogel-forming microneedles. In this method, polymer solutions containing the drug are cast into microstructured molds and then solidified through drying or crosslinking. It allows accurate control over microneedle geometry and is highly scalable.

Photolithography, derived from microelectronics, is used mainly for fabricating solid or coated silicon microneedles. It involves the use of light-sensitive resists and etching techniques to generate sharp and uniform needle structures. While it offers high precision, the process is expensive and less suitable for mass production.

Laser cutting and ablation techniques are useful for creating metallic microneedles. This approach provides fast, accurate shaping of metal sheets into microneedle arrays but may result in surface roughness that requires further polishing.

Drawing lithography enables fabrication by drawing a polymer droplet into a microneedle shape, often assisted by surface tension and thermal processing. This method supports rapid prototyping and flexibility in design.

3D printing, especially two-photon polymerization and stereolithography, is emerging as a powerful tool for custom microneedle fabrication. It offers design freedom, rapid development, and drug-free or drug-loaded microneedle constructs with complex architectures.

Table 1: Comparison of Microneedle Types

Type	Material	Drug Delivery Mode	Advantages	Limitations
Solid	Silicon, metal, polymers	Pre-treatment for drug diffusion	Simple design, reusable mold	Two-step process, limited drug control
Coated	Metal, silicon (with surface coating)	Coating dissolves after insertion	Rapid onset, suitable for vaccines	Low drug loading, coating uniformity issues
Dissolving	Biodegradable polymers (e.g., HA, CMC)	Microneedle dissolves in skin	Safe, single-use, eliminates sharp waste	Limited to low-dose drugs
Hollow	Glass, metal, silicon	Liquid injected through lumen	Precise dosing, suitable for larger volumes	Complex design, risk of clogging
Hydrogel-forming	Crosslinked hydrogels	Swells and draws drug from patch	Sustained release, reusable patch systems	Requires external drug reservoir

4. Clinical Applications of Microneedle Systems

Microneedle-based drug delivery systems have progressed from laboratory research to early clinical development, demonstrating potential across various therapeutic areas. Their ability to offer minimally invasive, targeted, and controlled drug administration makes them particularly attractive for chronic disease management, vaccination, and localized therapies [20].

4.1 Vaccination

Vaccination remains the most widely explored clinical application of microneedles. Several studies have demonstrated the successful delivery of influenza, measles, hepatitis B, and COVID-19 vaccines using dissolvable or coated microneedles. These systems enable antigen delivery to the skin's immunologically rich layers, enhancing immune response while eliminating the need for cold chain storage and trained personnel. In clinical trials, microneedle patches have shown comparable or superior immunogenicity to intramuscular injections with improved patient acceptability.

4.2 Diabetes Management

Microneedles offer promising applications in diabetes through transdermal delivery of insulin. Dissolving microneedles made from biocompatible polymers have been shown to deliver insulin effectively with sustained release, reducing the need for multiple daily injections. Smart microneedle patches with glucose-responsive release mechanisms are also under development to enable on-demand insulin delivery in response to blood glucose fluctuations.

4.3 Cancer Therapy

Microneedles can be used to deliver chemotherapeutic agents directly into tumors or through the skin for systemic absorption. Studies using doxorubicin-loaded microneedles have demonstrated significant tumor inhibition with reduced systemic toxicity. Combination microneedle systems that co-deliver chemotherapy and immunotherapy agents are being explored for synergistic effects.

4.4 Dermatological and Cosmetic Treatments

In dermatology, microneedles are used for localized delivery of corticosteroids, retinoids, and peptides for conditions such as psoriasis, alopecia, and hyperpigmentation. In cosmetics, microneedles enhance skin permeability for anti-aging, whitening, and rejuvenating agents. Their ability to stimulate dermal collagen production also adds a physical rejuvenation effect.

4.5 Infectious Disease and Antimicrobial Therapy

Microneedles are being explored for localized delivery of antibiotics and antiviral drugs to treat cutaneous infections, warts, and herpes. Their ability to bypass systemic circulation minimizes adverse effects while maximizing local therapeutic efficacy.

Table 2: Clinical Applications of Microneedle-Based Drug Delivery Systems

Application Area	Target Disease/Use	Microneedle Type	Key Benefits
Vaccination	Influenza, COVID-19, Measles, Hepatitis B	Dissolving, Coated	Enhanced immunity, painless, no cold chain, easy use
Diabetes Management	Type 1 and Type 2 Diabetes	Dissolving, Smart MNs	Sustained insulin delivery, patient-friendly, responsive
Cancer Therapy	Breast, skin, liver cancers	Solid, Coated, Dissolving	Localized delivery, reduced toxicity, tumor targeting
Dermatology/Cosmetics	Psoriasis, aging, pigmentation	Solid, Dissolving	Local delivery, cosmetic enhancement, collagen induction
Infectious Disease	Herpes, bacterial skin infections	Coated, Dissolving	Targeted antimicrobial action, minimized systemic effects

5. Conclusion

Microneedle-based drug delivery systems represent a significant advancement in transdermal therapeutics, offering a painless, precise, and patient-friendly alternative to conventional drug administration routes. Their ability to bypass the stratum corneum barrier, deliver both small and large molecules, and allow for self-administration makes them ideal for applications ranging from vaccination and diabetes management to cancer therapy and dermatology.

Recent innovations in microneedle materials, fabrication technologies, and drug release strategies have opened new frontiers for personalized and responsive drug delivery. Clinical studies have demonstrated not only their safety and efficacy but also enhanced patient compliance. However, challenges such as large-scale manufacturing, regulatory standardization, long-term biocompatibility, and market access remain. Addressing these limitations through interdisciplinary collaboration and continued innovation will be key to the successful translation of microneedle systems from lab to clinic.

With growing interest from both academia and industry, microneedles are poised to play a pivotal role in the future of drug delivery, especially in the era of precision medicine and decentralized healthcare.

Conflict of Interest

The authors declare no conflict of interest.

Funding

No Funding was received.

Refrences

Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261–8.

Ita K. Transdermal delivery of drugs with microneedles—potential and challenges. Pharmaceutics. 2015;7(3):90–105.

Donnelly RF, Singh TRR, Woolfson AD. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv. 2010;17(4):187–207.

Bariya SH, Gohel MC, Mehta TA, Sharma OP. Microneedles: an emerging transdermal drug delivery system. J Pharm Pharmacol. 2012;64(1):11–29.

Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012;64(14):1547–68.

Norman JJ, Prausnitz MR. Microneedle patches: Usability and acceptability for self-vaccination against influenza. Vaccine. 2015;33(43):5666–71.

Coulman SA, Allender CJ, Birchall JC. Microneedles and other physical methods for overcoming the stratum corneum barrier for cutaneous gene therapy. Hum Gene Ther. 2006;17(10):1019–28.

Rzhevskiy AS, Singh TRR, Donnelly RF, Anissimov YG. Microneedles as the technique of drug delivery enhancement in diverse organs and tissues. J Control Release. 2018;270:184–202.

Sullivan SP, Koutsonanos DG, Martin MD, et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med. 2010;16(8):915–20.

Kolli CS, Banga AK. Characterization of solid maltose microneedles and their use for transdermal delivery. Pharm Res. 2008;25(1):104–13.

Gill HS, Denson DD, Burris BA, Prausnitz MR. Effect of microneedle design on pain in human subjects. Clin J Pain. 2008;24(7):585–94.

Chen MC, Ling MH, Kusuma SJ, et al. A polymeric microneedle patch for minimally-invasive transdermal delivery of insulin. J Control Release. 2012;161(3):933–41.

Arya J, Prausnitz MR. Microneedle patches for vaccination in developing countries. J Control Release. 2016;240:135–41.

Larrañeta E, Lutton RE, Woolfson AD, Donnelly RF. Microneedle arrays as transdermal and intradermal drug delivery systems: materials science, manufacture and commercial development. Mater Sci Eng R Rep. 2016;104:1–32.

Lee K, Lee CY, Jung H. Dissolving microneedles for transdermal drug administration prepared by stepwise controlled drawing of maltose. Biomaterials. 2011;32(11):3134–40.

Zhang Y, Yu J, Bomba HN, et al. Nanoparticle-laden dissolving microneedles for cancer immunotherapy. Adv Mater. 2017;29(17):1604043.

Gupta J, Felner EI, Prausnitz MR. Rapid pharmacokinetics of intradermal insulin administered using microneedles in type 1 diabetes subjects. Diabetes Technol Ther. 2011;13(4):451–6.

Wilke N, Mulcahy A, Ye SR, Morrissey A. Process optimization and characterization of silicon microneedles fabricated by wet etch technology. Microelectron J. 2005;36(7):650–6.

Park JH, Allen MG, Prausnitz MR. Biodegradable polymer microneedles: fabrication, mechanics and transdermal drug delivery. J Control Release. 2005;104(1):51–66.

Yang H, Wu F, Liu S, et al. Skin biopharmaceutical delivery: concepts, advances and challenges. J Control Release. 2021;331:1022–39.